Syllabus: GS2/ Health, GS3/ Science and Technology
Context
- A research on Candida auris demonstrates that resistance to antifungals can arise through gene mutation, gene duplication and compensatory mechanisms in the cell.
What are Fungal Infections?
- Fungal infections are diseases caused by pathogenic fungus that can damage the skin, nails, lungs, blood stream and other organs.
- Dermatophytes are fungi that are common causes of skin, nail and hair infection, while yeasts such as Candida auris can cause severe systemic infection.
- Fungal infections are particularly hazardous in immunocompromised individuals because they can become invasive and life-threatening.
Why is Candida auris a concern?
- Candida auris is a developing multidrug-resistant yeast that causes bloodstream and other invasive infections, notably in health care settings.
- It was first identified in Japan in 2009 and has since been reported in several nations.
- In India, more than 90% of the clinical isolates of C. auris tested were resistant to azole antifungals such as fluconazole, and many were also resistant to polyenes.
Why is Antifungal Resistance Increasing?
- Global Warming: Most fungi cannot normally survive well at the human body temperature, which limits their ability to infect humans.
- Rising global temperatures favour heat-tolerant fungi that can gradually adapt to warmer conditions.
- Frequent or inappropriate use of antifungal medicines puts selection pressure on fungi, allowing resistant strains to survive and multiply.
- Limited Diagnostic Facilities: Many healthcare facilities lack adequate capacity to identify fungal species and test their drug susceptibility.
- As a result, infections may be treated with ineffective medicines, allowing resistant fungi to persist.
- Limited Treatment Options: Unlike bacteria, fungi have fewer biological differences from human cells, making it difficult to develop drugs that selectively kill fungi without harming the patient.
The Eagle Effect
- The Eagle effect is the paradoxical phenomenon where some fungi, when exposed to a low concentration of an antifungal, survive or re-grow when exposed to a very high concentration.
- In C. auris, this can occur because high drug concentrations activate compensatory pathways such as increased chitin synthesis.
- Therefore, an increase in the amount of antifungal does not always ensure a larger therapeutic benefit.
What are the challenges?
- Many healthcare facilities lack adequate fungal diagnostic and identification infrastructure.
- Conventional susceptibility testing may not fully capture unusual resistance mechanisms such as paradoxical growth.
- Advanced genomic testing to identify resistance-associated mutations can be expensive and difficult to deploy routinely.
- Limited availability of effective antifungal classes increases the risk of therapeutic failure.
- Weak surveillance can delay the identification of emerging resistant fungal strains.
Way Ahead
- Strengthen fungal surveillance: Establish integrated national surveillance systems for emerging and drug-resistant fungal pathogens.
- Improve diagnostics: Expand access to fungal culture, antifungal susceptibility testing and genomic methods, particularly in tertiary hospitals.
- One Health approach: Antifungal resistance should be studied across human, animal and environmental ecosystems, particularly in the context of climate change.
Source: TH
Previous article
India-New Zealand FTA